Announcements
- Sandoz reports first quarter 2024 sales
- Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
- Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
- Sandoz reports fourth quarter 2023 sales and full-year 2023 results
- Sandoz receives FDA approval for first and only denosumab biosimilars
- Sandoz announces nominations to the Board of Directors and leadership change
- Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
- Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
More ▼
Key statistics
As of last trade Sandoz Group AG (D8Y:BRN) traded at 32.58, -0.46% below its 52-week high of 32.73, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.46 |
---|---|
High | 32.58 |
Low | 32.46 |
Bid | 28.00 |
Offer | -- |
Previous close | 32.35 |
Average volume | 66.17 |
---|---|
Shares outstanding | 431.00m |
Free float | 395.66m |
P/E (TTM) | -- |
Market cap | 13.81bn CHF |
EPS (TTM) | -- |
Annual div (ADY) | 0.45 CHF |
---|---|
Annual div yield (ADY) | 1.38% |
Div ex-date | May 03 2024 |
Div pay-date | May 07 2024 |
Data delayed at least 15 minutes, as of May 17 2024.
More ▼